XTX Topco Ltd Takes Position in Ascendis Pharma A/S (NASDAQ:ASND)

Key Points

• XTX Topco Ltd acquired a new position in Ascendis Pharma A/S, purchasing 3,746 shares valued at approximately $584,000 during the first quarter of the year.
• Analysts have set new price targets for Ascendis Pharma A/S, with estimates ranging from $200.00 to $280.00, and the stock currently holds an average rating of "Moderate Buy."
• Ascendis Pharma's stock has shown significant price movement, opening at $186.59 while having a 12-month range from $111.09 to $186.89.

XTX Topco Ltd purchased a new position in Ascendis Pharma A/S (NASDAQ:ASND - Free Report) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 3,746 shares of the biotechnology company's stock, valued at approximately $584,000.

Other large investors also recently modified their holdings of the company. RA Capital Management L.P. boosted its position in Ascendis Pharma A/S by 4.1% in the fourth quarter. RA Capital Management L.P. now owns 10,112,744 shares of the biotechnology company's stock worth $1,392,221,000 after purchasing an additional 402,316 shares during the last quarter. Avoro Capital Advisors LLC lifted its stake in shares of Ascendis Pharma A/S by 2.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 5,103,055 shares of the biotechnology company's stock worth $702,538,000 after purchasing an additional 114,167 shares during the period. Janus Henderson Group PLC boosted its holdings in shares of Ascendis Pharma A/S by 4.6% in the fourth quarter. Janus Henderson Group PLC now owns 4,380,382 shares of the biotechnology company's stock worth $602,910,000 after buying an additional 193,688 shares during the last quarter. Capital International Investors boosted its holdings in shares of Ascendis Pharma A/S by 35.7% in the fourth quarter. Capital International Investors now owns 2,863,249 shares of the biotechnology company's stock worth $394,183,000 after buying an additional 753,859 shares during the last quarter. Finally, T. Rowe Price Investment Management Inc. grew its position in Ascendis Pharma A/S by 54.4% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 2,725,546 shares of the biotechnology company's stock valued at $375,226,000 after buying an additional 960,504 shares during the period.

Ascendis Pharma A/S Price Performance

Shares of ASND stock traded up $1.14 during trading hours on Friday, hitting $191.49. The stock had a trading volume of 1,554,046 shares, compared to its average volume of 464,205. The stock has a market capitalization of $11.71 billion, a price-to-earnings ratio of -37.11 and a beta of 0.41. Ascendis Pharma A/S has a one year low of $111.09 and a one year high of $199.99. The stock's 50-day moving average price is $174.03 and its two-hundred day moving average price is $158.83.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last announced its earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, beating the consensus estimate of ($1.42) by $0.49. The firm had revenue of $216.28 million during the quarter, compared to analysts' expectations of $163.17 million. As a group, equities research analysts predict that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on ASND shares. Morgan Stanley began coverage on shares of Ascendis Pharma A/S in a research note on Thursday, July 3rd. They set an "overweight" rating and a $250.00 price target on the stock. Wells Fargo & Company reaffirmed an "overweight" rating and issued a $295.00 target price (up from $289.00) on shares of Ascendis Pharma A/S in a report on Friday. Cantor Fitzgerald boosted their price target on Ascendis Pharma A/S from $200.00 to $203.00 and gave the company an "overweight" rating in a report on Friday. UBS Group upped their price target on Ascendis Pharma A/S from $306.00 to $307.00 and gave the stock a "buy" rating in a research report on Friday. Finally, Royal Bank Of Canada raised their price objective on Ascendis Pharma A/S from $210.00 to $230.00 and gave the stock an "outperform" rating in a research note on Friday. Sixteen investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Ascendis Pharma A/S currently has a consensus rating of "Buy" and a consensus target price of $239.80.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.